| Name | Atchison Hospital |
|---|---|
| Type | Critical Access Hospital |
| Location | 800 Ravin Hill Drive, Atchison, Kansas |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | Yes |
| Medicare ID (CCN) | 171382 |
| NPI Number | 1629308192 |
| Organization Name | ATCHISON HOSPITAL EMERGENCY DEPARTMENT |
| Address | 1301 N 2nd St, Atchison, KS 66002 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 913-360-5810 |
News Archive
Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.
You're forgiven if in the holiday rush you missed the news last month that a federal appeals court in New Orleans once again put the future of the Affordable Care Act in doubt and ordered a lower court to review its fate.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
News-Medical speaks to Dr. Albert Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19.
› Verified 7 days ago
| NPI Number | 1700055837 |
| Organization Name | ATCHISON HOSPITAL ASSOCIATION |
| Doing Business As | EMERGENCY DEPT PRO FEE |
| Address | 800 Raven Hill Drive, Atchison, KS 66002 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 913-367-2131 |
News Archive
Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.
You're forgiven if in the holiday rush you missed the news last month that a federal appeals court in New Orleans once again put the future of the Affordable Care Act in doubt and ordered a lower court to review its fate.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
News-Medical speaks to Dr. Albert Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19.
› Verified 7 days ago
| NPI Number | 1801122353 |
| Organization Name | ATCHISON HOSPITAL |
| Address | 1301 N 2nd St, Atchison, KS 66002 |
| Hospital Type | General Acute Care Hospital - Rural |
| Phone Number | 913-367-2131 |
News Archive
Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.
You're forgiven if in the holiday rush you missed the news last month that a federal appeals court in New Orleans once again put the future of the Affordable Care Act in doubt and ordered a lower court to review its fate.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
News-Medical speaks to Dr. Albert Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19.
› Verified 7 days ago
| NPI Number | 1932151487 |
| Organization Name | AMBERWELL ATCHISON ASSOCIATION |
| Doing Business As | AMBERWELL ATCHISON |
| Address | 800 Raven Hill Drive, Atchison, KS 66002 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 913-367-2131 |
News Archive
Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.
You're forgiven if in the holiday rush you missed the news last month that a federal appeals court in New Orleans once again put the future of the Affordable Care Act in doubt and ordered a lower court to review its fate.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
News-Medical speaks to Dr. Albert Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19.
› Verified 7 days ago
| Able to receive lab results electronically | Not Available |
| Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.
You're forgiven if in the holiday rush you missed the news last month that a federal appeals court in New Orleans once again put the future of the Affordable Care Act in doubt and ordered a lower court to review its fate.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
News-Medical speaks to Dr. Albert Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19.
› Verified 7 days ago
Atchison Hospital Critical Access Hospital Location: 800 Ravin Hill Drive, Atchison, Kansas 66002 Phone: (913) 360-5581 |